Antisense oligonucleotide–mediated MSH3 suppression reduces somatic CAG repeat expansion in Huntington’s disease iPSC–derived striatal neurons
Science Translational Medicine · 12.02.2025 · 17 (785)
DOI: 10.1126/scitranslmed.adn4600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 12.02.2025. Verfasst von Emma L Bunting und 20 weiteren Autor:innen. Beteiligte Einrichtung: Huntington's Disease Centre and Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology and UK Dementia Research Institute, …. Hauptthemen laut MEDLINE: Huntington Disease, Induced Pluripotent Stem Cells, Neurons, Oligonucleotides, Antisense. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 89 Literaturangaben.
Abstract (Originalsprache)
Expanded CAG alleles in the huntingtin ( HTT ) gene that cause the neurodegenerative disorder Huntington’s disease (HD) are genetically unstable and continue to expand somatically throughout life, driving HD onset and progression. MSH3, a DNA mismatch repair protein, modifies HD onset and progression by driving this somatic CAG repeat expansion process. MSH3 is relatively tolerant of loss-of-function variation in humans, making it a potential therapeutic target. Here, we show that an MSH3 -targeting antisense oligonucleotide (ASO) effectively engaged with its RNA target in induced pluripotent stem cell (iPSC)–derived striatal neurons obtained from a patient with HD carrying 125 HTT CAG repeats (the 125 CAG iPSC line). ASO treatment led to a dose-dependent reduction of MSH3 and subsequent stalling of CAG repeat expansion in these striatal neurons. Bulk RNA sequencing revealed a safe profile for MSH3 reduction, even when reduced by >95%. Maximal knockdown of MSH3 also effectively slowed CAG repeat expansion in striatal neurons with an otherwise accelerated expansion rate, derived from the 125 CAG iPSC line where FAN1 was knocked out by CRISPR-Cas9 editing. Last, we created a knock-in mouse model expressing the human MSH3 gene and demonstrated effective in vivo reduction in human MSH3 after ASO treatment. Our study shows that ASO-mediated MSH3 reduction can prevent HTT CAG repeat expansion in HD 125 CAG iPSC–derived striatal neurons, highlighting the therapeutic potential of this approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Huntington's Disease Centre and Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology and UK Dementia Research Institute, UCL, London, UK.
- School of Molecular Biosciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
- UK Dementia Research Institute at University of Cambridge and Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0AH, UK.
- Department of Molecular Neuroscience, Transylvanian Institute of Neuroscience, 400191 Cluj-Napoca, Romania.
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Ionis Pharmaceuticals, Carlsbad, CA, USA.
ORCID-Profile: Emma L Bunting, Jasmine Donaldson, Sarah A Cumming, Jessica Olive, Elizabeth Broom, Mihai Miclăuș, Joseph Hamilton, Matthew Tegtmeyer, Jonathan Brenton, Won-Seok Lee, Robert E Handsaker, Brittany Ford, Mina Ryten, Gabriel Balmus, Sarah J Tabrizi
Zitieren
APA
Bunting, E. L., Donaldson, J., Cumming, S. A., Olive, J., Broom, E., Miclăuș, M., Hamilton, J., Tegtmeyer, M., Zhao, H. T., Brenton, J., Lee, W. S., Handsaker, R. E., Li, S., Ford, B., Ryten, M., McCarroll, S. A., Kordasiewicz, H. B., Monckton, D. G., Balmus, G., …, & Tabrizi, S. J. (2025). Antisense oligonucleotide–mediated MSH3 suppression reduces somatic CAG repeat expansion in Huntington’s disease iPSC–derived striatal neurons. Science Translational Medicine, 17(785). https://doi.org/10.1126/scitranslmed.adn4600
Vancouver
Bunting EL, Donaldson J, Cumming SA, Olive J, Broom E, Miclăuș M, et al. Antisense oligonucleotide–mediated MSH3 suppression reduces somatic CAG repeat expansion in Huntington’s disease iPSC–derived striatal neurons. Science Translational Medicine. 2025;17(785). doi:10.1126/scitranslmed.adn4600
BibTeX
@article{Bunting2025,
author = {Bunting, Emma L and Donaldson, Jasmine and Cumming, Sarah A and Olive, Jessica and Broom, Elizabeth and Miclăuș, Mihai and Hamilton, Joseph and Tegtmeyer, Matthew and Zhao, Hien T and Brenton, Jonathan and Lee, Won-Seok and Handsaker, Robert E and Li, Susan and Ford, Brittany and Ryten, Mina and McCarroll, Steven A and Kordasiewicz, Holly B and Monckton, Darren G and Balmus, Gabriel and Flower, Michael and Tabrizi, Sarah J},
title = {Antisense oligonucleotide–mediated MSH3 suppression reduces somatic CAG repeat expansion in Huntington’s disease iPSC–derived striatal neurons},
journal = {Science Translational Medicine},
year = {2025},
volume = {17},
number = {785},
doi = {10.1126/scitranslmed.adn4600}
}
EUVIMED